Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Subcutaneous Partnerships Are Stepping Stones: Halozyme Touts Its Insulin Product

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite multiple partnerships around a technology platform that can ease administration of existing drugs, Halozyme says its future prospects revolve more around a significant opportunity in insulin-pump products.

You may also be interested in...

Safety Petition Against Baxter’s Immune Globulin HyQvia Could Limit Use

Last-minute petitions traditionally target ANDAs, but this submission raises concerns about a BLA for a product trying to stand out in the relatively undifferentiated immune globulin market.

ViroPharma Talks Cinryze Sales, EU Launches

ViroPharma assures investors that its lead product Cinryze is growing and that launches in the EU are on track during an analyst day presentation.

Subcutaneous Herceptin Meets Goals In Phase III Trial

New subcutaneous formulation of Roche's breast cancer biologic Herceptin is comparable to intravenous version, prompting the companies to file for approval in Europe in 2012. Yet, U.S. filing could take longer.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts